| First Author | Wang X | Year | 2018 |
| Journal | Mol Med Rep | Volume | 17 |
| Issue | 1 | Pages | 1660-1666 |
| PubMed ID | 29138852 | Mgi Jnum | J:308046 |
| Mgi Id | MGI:6727855 | Doi | 10.3892/mmr.2017.8048 |
| Citation | Wang X, et al. (2018) AntiIL39 (IL23p19/Ebi3) polyclonal antibodies ameliorate autoimmune symptoms in lupuslike mice. Mol Med Rep 17(1):1660-1666 |
| abstractText | The interleukin (IL)12 family cytokines have been examined as therapeutic targets in the treatment of several autoimmune diseases. Our previous study showed that a novel IL12 family cytokine, IL39 (IL23p19/Ebi3) mediates inflammation in lupuslike mice. In the present study, the effect of antimouse IL39 polyclonal antibodies on autoimmune symptoms in lupuslike mice was investigated. Rabbit antimouse IL39 polyclonal antibodies were produced by immunization with recombinant mouse IL39, and purified using protein A chromatography. These antibodies were subsequently used to treat lupuslike mice. Flow cytometry, captured images, ELISA and H&E staining were used to determine the effect of antiIL39 polyclonal antibodies on inflammatory cells, autoantibody titers, proteinuria, infiltrating inflammatory cells and the structure of the glomerular region. The antiIL39 polyclonal antibodies effectively reduced the numbers of inflammatory cells, splenomegaly, autoantibody titers, proteinuria, infiltrating inflammatory cells, and restored the structure of the glomerular region in MRL/lpr mice. Taken together, these results suggested that antiIL39 polyclonal antibodies ameliorated autoimmune symptoms in lupuslike mice. Therefore, IL39 may be used as a possible target for the treatment of systemic lupus erythematosus. |
